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A B S T R A C T
Blood for determining 25-hydroxyvitamin D3 [25(OH)D3] is usually obtained through venipuncture although, as
an alternative for serum, dried blood spot (DBS) can be considered. The aim of this proof-of-concept study was to
investigate levels of agreement between measurements of 25(OH)D3 obtained with DBS compared with serum.
301 Chinese participants were included who completed 25(OH)D3 measurement from DBS and from simulta-
neously collected blood samples obtained by venipuncture. Measurements of both DBS and serum 25(OH)D3
were performed using liquid chromatography followed by tandem mass spectrometry. Agreement between the
two methods was assessed with Passing and Bablok regression analysis and Bland-Altman plot.
Measurements showed a good correlation (Pearson’s correlation coefficient r= 0.929, P < 0.001) between
the two methods. After recalculating for a 13% difference, a regression equation of DBS 25(OH)D3 =
-1.91+ 1.00 serum 25(OH)D3 was found in Passing and Bablok regression analysis. Bland-Altman analysis
showed a fixed bias of 1.7 nmol/L; upper and lower limit of agreement was 24.1 nmol/L and -20.7 nmol/L,
respectively.
Sensitivity of recalculated DBS for 25(OH)D3 concentrations< 30 and<50 nmol/L was 87.8% and 91.1%,
respectively, and specificity was 89.2% and 83.1%, respectively.
In conclusion, a good agreement was found between the measurement of 25(OH)D3 obtained with DBS
compared with serum. DBS may possibly be used in a future screening program, but it is less suitable for in-
dividualized vitamin D status assessment.
1. Introduction
Vitamin D3 is produced in the skin when exposed to ultraviolet light
irradiation from its precursor 7-dehydrocholesterol. In the liver, vi-
tamin D3 is rapidly hydroxylated into 25-hydroxyvitamin D3 [25(OH)
D3], which is the major circulating metabolite and considered the best
indicator of vitamin D status.
In the Netherlands, margarine and baking oils are fortified with
vitamin D3 (7.5 μg/100 g). Vitamin D supplements prescribed by phy-
sicians in the Netherlands all contain vitamin D3. Also, almost all vi-
tamin D2, originated from irradiation of the plant sterol ergosterol, in
multivitamin tablets in the Netherlands has been replaced by vitamin
D3.
The Health Council of the Netherlands uses cut-off points for
25(OH)D3 of 30 nmol/L for vitamin D deficiency and risk of rickets and
of 50 nmol/L above which no further improvement of bone health is
expected [1]. Based on their data, the Institute of Medicine suggests
that persons are at risk of deficiency relative to bone health at serum
25(OH)D levels of below 30 nmol/L, and that practically all persons are
sufficient at serum 25(OH)D levels of at least 50 nmol/L [2].
Many large-scale epidemiological and clinical studies on vitamin D
have been conducted. Blood sampling for disease diagnosis and ther-
apeutic drug monitoring is usually obtained by venipuncture. However,
large-scale studies may be hampered by this kind of blood collection
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due to emotional, psychological, physical, and/or organizational bar-
riers. For example, i) in older persons it may be difficult to draw blood
[3], ii) for infants and children, painless blood collection and a low
sample volume are important conditions [4], iii) in developing coun-
tries, access to a phlebotomy service may be limited (especially in re-
mote areas) decreasing study participation.
Recently, dried blood spot (DBS) techniques for measurements of
25(OH)D3 have been developed as an alternative for venipuncture
[5–8]. This method for 25(OH)D3 measurement is minimally invasive,
requires a smaller volume of blood than venipuncture and (with ade-
quate training) is suitable for patients to self-sample at home. Dried
blood spots of 25(OH)D3 are stable at room temperature and can easily
be transported and long-term stored [5]. The method involves the
collection of blood (by a finger prick) that is dropped onto filter paper
and allowed to dry.
Observational studies have explored the use of DBS for assessment
of vitamin D status [9–11]. Others compared measurement of 25(OH)
D3 using DBS as compared with serum or whole blood and reported
relatively good agreement between these two methods [4,12]. How-
ever, despite these positive results, DBS is not commonly used in the
Netherlands, raising the question as to whether DBS could replace
conventional venous sampling for measurement of 25(OH)D3 con-
centrations.
Therefore, in a sample of Chinese individuals residing in the
Netherlands, this proof-of-concept study examines whether DBS mea-
surements of 25(OH)D3, using a method developed in the Netherlands,
correspond with concentrations measured in serum.
2. Subjects and methods
As part of an observational study with a total of 418 persons to
determine vitamin D status in the Chinese population in the
Netherlands (performed in March 2014) [13], in the present study a
subgroup of 301 participants completed 25(OH)D3 measurement from
blood spot samples and from simultaneously collected blood samples
obtained by venipuncture. Briefly, participants aged ≥18 years with a
Chinese background and residing in the Netherlands were eligible to
participate when they, or at least one of their parents, were born in
mainland China, Hong Kong or Taiwan.
The study protocol was approved by the Medical Ethical Committee
of the Leiden University Medical Center and was conducted in ac-
cordance with the principles of the Declaration of Helsinki. All parti-
cipants gave written informed consent.
2.1. Methods
Blood spot cards used for the measurement of DBS 25(OH)D3 were
purchased from and analyzed by the Dried Blood Spot Laboratory
(DBSL, Geleen, the Netherlands). Certified nurses collected both venous
and DBS blood from the participants. Using single-use lancets, a drop of
blood was formed and allowed to drop freely onto the filter paper
(Whatman 903®) of the sample cards. For each participant, two non-
overlapping drops of blood were collected in pre-marked circles printed
on the filter cards. After drying for ≥15min at room temperature and
further drying in a special shipping box (containing a silica gel sachet as
a drying agent) the cards were sent by postal service to the laboratory of
DBSL and analyzed by liquid chromatography followed by tandem mass
spectrometry (LC–MS/MS).
2.2. LC–MS/MS settings and detection by DBSL
The LC–MS/MS method used by the laboratory (DBSL) is a further
development of Eyles’ method [5]. Chromatography (Agilent 1290
binary pump, autosampler, thermostat, and column compartment) was
performed using an Acquity C18 column (Waters), 150mm x 2.1mm,
1.7 μm particle size, and detection was performed using triple-
quadrupole mass spectrometry (Agilent 6460C LC–MS/MS) with an ESI
source. The detection of ions of a specific fragment was performed using
multiple reaction monitoring (MRM mode). Mobile phase A consisted of
water containing 0.38 g/L ammonium acetate and 6ml/L 2-methyl-2-
butanol; mobile phase B consisted of methanol containing 0.38 g/L
ammonium acetate and 6ml/L 2-methyl-2-butanol. The column com-
partment temperature was 75 °C and the injection volume was 5 μL.
Mass parameter settings were: 25(OH)D3-PTAD, m/z 558.4 Da
-> 298.1 Da, collision energy 15 eV; internal standard (25(OH)D3-d3),
m/z 561.4 Da -> 301.1 Da, collision energy 15 eV.
2.3. Calibration by DBSL
First, calibration standards for 25(OH)D3 were prepared. As 25(OH)
D3 is an endogenous compound, all human blood samples contain
25(OH)D3 and, therefore, no blank samples are available. DBSL has
chosen to spike artificial vitamin D free serum with standard reference
material (SRM) 2972a (in ethanol) (NIST, Gaithersburg, MD, USA) and
mixed this with washed red blood cells (RBC) to produce blood with a
hematocrit of 0.45. The prepared standards were mixed gently for
30min at room temperature directly followed by the preparation of the
DBS samples by applying 30 μL of the blood standard to the paper.
Calibration was performed with these DBS reference samples of known
content.
Quality control samples were made using serum reference material
(LabQuality, Helsinki, Finland) by mixing these with washed RBC to
produce a hematocrit of 0.45.
2.4. Sample preparation by DBSL
Prior to sample preparation, a solution of 75 μL internal standard
(IS) (100 nmol/L) [Tri deutero-25-hydroxycholecalciferol (25(OH)D3-
d3) Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands] in a solvent
containing 1 N NaOH, 0.25% Tween-20 and 2 g/L tetra butyl ammo-
nium bromide (used as an ion-pairing reagent to improve extraction
recovery as it is believed to release adsorbed 25(OH)D3 from the active
places on the Whatman 903® filter paper) was transferred into a Sarsted
tube followed by the addition of DBS by punching a circle of 8mm out
of the blood spot. Next, the tube was sonicated for 5min to release
25(OH)D3 from vitamin D binding protein. Subsequently, for depro-
teination a 50% acetonitrile/zinc sulphate (0.1M) solution was added,
followed by 30min sonication. For extraction of 25(OH)D3 hexane was
added. After mixing, the hexane layer was removed and evaporated to
dryness. For derivatization, to enhance detectability, a solution of
0.02% 4-Phenyl-1,2,4-Triazoline-3,5-Dione (PTAD) was added. The
resulting product was evaporated to dryness and reconstituted in mo-
bile phase B for analysis.
The lower limit of quantitation was 9.75 nmol/L with an overall
precision [intra-assay coefficient of variation (CV)] of 13.9%, and an
overall accuracy (bias) of 5.7% (N=6). For concentrations between
48–140 nmol/L [SRM 1 (76.4 nmol/L), SRM 2 (48.3 nmol/L), SRM 3
(49.04 nmol/L), SRM 4 (139.2 nmol/L)] the CV values were 8.7%,
9.8%, 9.9%, and 7.6% (N=6), respectively; bias was 2.0%, -8.7%,
-3.6%, and 7.9% (N=6), respectively. Recovery, which was about
76%, was established by comparing blood standards with spiked blank
samples of the same concentration.
2.5. Measurement of the serum 25(OH)D concentration
Simultaneously with blood spot collection, blood samples were
obtained by venipuncture from all participants. After centrifugation,
serum samples for 25(OH)D measurement by isotope dilution/online
solid-phase extraction liquid chromatography tandem mass spectro-
metry (ID-XLC-MS/MS) was performed at the Endocrine Laboratory of
the Amsterdam UMC, Vrije Universiteit Amsterdam [14], with only
minor adjustments [15]. In short, deuterated internal standard [25(OH)
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D3-d6] was added to the samples and 25(OH)D was released from its
binding proteins with acetonitrile. Samples were extracted and ana-
lyzed by XLC-MS/MS [a Symbiosis online SPE system (Spark Holland,
Emmen, the Netherlands)] coupled to a Quattro Premier XE tandem
mass spectrometer (Waters Corp., Milford, MA, USA). The limit of
quantitation was 4.0 nmol/L; intra-assay CV was< 6%, and interassay
CV was< 8% for concentrations of 25–180 nmol/L.
The Endocrine Laboratory participates with this 25(OH)D method in
the Vitamin D External Quality Assessment Scheme (DEQAS). The long
term CV% (over years) of the internal serum controls is< 10% for all
concentrations. Moreover, this method was well standardized by com-
paring this method with the reference method procedures (RMP) of the
University of Ghent in 40 serum samples collected by the US Center for
Disease Control and Prevention (CDC, Atlanta). This comparison
showed a very good agreement with the reference method [16].
3. Statistical analyses
Initially, both methods were compared with Pearson’s correlation
coefficient. Further comparison between DBS and serum samples was
performed by Passing and Bablok regression analysis, and Bland-
Altman analysis was used to calculate bias. A systematic difference (%)
found in Passing and Bablok analysis was used to recalculate bias in
Bland-Altman analysis.
Sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) of recalculated DBS for 25(OH)D3 concentra-
tions< 30 and<50 nmol/L were also calculated.
Statistical significance was considered at a P-value<0.05. Analyses
were performed using MedCalc® for Windows, version 17.6 (MedCalc
Software, Ostend, Belgium).
4. Results
Of the subgroup of 301 participants (83 males, 218 females) who
completed 25(OH)D3 measurements from blood spot samples and blood
samples obtained by venipuncture, 12 (4%) DBS samples (analyzed
singularly because the blood spots were too small to punch out a spot of
8mm) were excluded, leaving 289 samples suitable for analysis. The
mean age of these men and women was 55.8 ± 14.6 years and
57.2 ± 11.0 years, respectively. Self-reported use of vitamin D sup-
plements was 18.4% in men and 35.5% in women; the estimated
average quantity vitamin D was 12.5 μg and 16.25 μg per day, respec-
tively (data not shown).
Since the distribution of serum 25(OH)D3 concentration was
skewed, median 25(OH)D3 concentrations were calculated. Median
25(OH)D3 concentration for DBS was 39 [IQR, 27–56] nmol/L and for
serum was 47 [IQR, 35–69] nmol/L (P < 0.001). Serum 25(OH)D3
was<30 nmol/L in 18.5% of the population, between 30–50 nmol/L in
38.2%, and ≥50 nmol/L in 43.3%.
Results from the two methods of 25(OH)D3 measurements were
acceptably close, as expressed in a Passing and Bablok regression
equation DBS 25(OH)D3 = -1.53 (95% CI, -3.60, 0.64) + 0.87 (95% CI,
0.82, 0.92) serum 25(OH)D3 (Fig. 1); this implies a systematic 13%
lower DBS 25(OH)D3 concentration compared to serum 25(OH)D3
concentration, with no significant intercept difference. The Cusum test
for linearity did not show a significant deviation from linearity
(P= 0.33). Pearson’s correlation coefficient was 0.929 (P < 0.001).
Using the systematic difference of 13% as found in the Passing and
Bablok equation to reanalyze Bland-Altman analysis, a significant fixed
bias of 1.7 nmol/L (95% CI, 0.4, 3.0) was found. Upper (mean + 1.96
SD) and lower (mean – 1.96 SD) limit of agreement was 24.1 nmol/L
and -20.7 nmol/L, respectively (Fig. 2).
As we regard a fixed bias of 1.7 nmol/L as not clinically relevant, we
used the systematic difference of 13% to recalculate DBS 25(OH)D3
concentration by multiplying DBS 25(OH)D3 concentrations with factor
100/87. After recalculation the Passing and Bablok equation was DBS
25(OH)D3 = -1.91 (95% CI, -4.45, 0.59) + 1.00 (95% CI, 0.95, 1.06)
serum 25(OH)D3, with no significant intercept or slope difference. The
Cusum test was not significant (P=0.26), i.e. no significant deviation
from linearity.
Sensitivity of recalculated DBS for 25(OH)D3 concentrations< 30
and< 50 nmol/L was 87.8% and 91.1%, respectively, and specificity
was 89.2% and 83.1%, respectively. The PPVs for recalculated DBS
were 62.3% and 86.7%, respectively, and the NPVs were 97.3 and
88.5%, respectively (Table 1).
Fig. 1. Passing and Bablok plot of 25(OH)D3 measured in dried blood spot
(DBS) compared to serum in 289 simultaneously collected samples, with re-
gression line and confidence bands for regression line. Identity line is dashed.
Fig. 2. Bland-Altman plot (difference plot) of 25(OH)D3 measurement com-
paring dried blood spot (DBS) samples and venous blood samples using LC–MS/
MS.
Table 1
Sensitivity (SE), specificity (SP), positive predictive value (PPV), and negative
predictive value (NPV) of recalculated dried blood spot for 25(OH)D3 con-
centrations of< 30 nmol/L and<50 nmol/L.
< 30 nmol/L <50 nmol/L
SE (%) 87.8 91.1
SP (%) 89.2 83.1
PPV (%) 62.3 86.7
NPV (%) 97.3 88.5
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5. Discussion
In this study, a good agreement was found between measurements
of 25(OH)D3 obtained with DBS compared with serum. After correction
for the 13% systematic difference a fixed bias of 1.7 nmol/L was found
and no significant constant or proportional differences were observed in
Passing and Bablok analysis.
Our results support studies that found good agreement between
measurements of 25(OH)D from DBS and plasma or serum samples. In
one study, no significant difference was found between 25(OH)D3
concentrations in DBS compared to serum [7]. Another study reported
(on average) lower DBS levels compared to plasma, even after correc-
tion of DBS value for mean sex-specific hematocrit levels [12]. This was
explained by physiological variation in hematocrit levels, diminished
sample extraction of DBS, and degradation of DBS during approxi-
mately 20 years of storage. In another study comparing DBS to serum or
whole blood samples, a good (but imperfect) agreement was shown, in
which DBS was (on average) slightly lower than serum measurement
[4].
In the present study, we also found lower 25(OH)D3 concentrations
in DBS compared to matching sera. However, although we cannot ac-
count for the systematic difference found in our analysis, differences in
the standardization of the methods may partially explain this. For ex-
ample, the use of different calibration or preparation standards, and
differences in operation procedures between the two methods may have
an effect on bias.
As almost all circulating 25(OH)D3 is bound to vitamin D binding
protein [17] and, since this component is excluded from RBC, almost all
of the 25(OH)D3 is found in the serum component of whole blood [18].
Therefore, to compare DBS and serum, the influence of the hematocrit
fraction should be taken into account. For example, the viscosity of
blood increases with increased hematocrit and, thus, the spread of
blood on the DBS cards could vary depending on the hematocrit. In
general, there is an inverse relationship between blood hematocrit and
spot area [19], i.e., a punch of a fixed blood spot will contain more
blood in case of a high-hematocrit sample compared to a low-hemato-
crit sample due to the higher viscosity of blood. However, DBSL uses a
comparatively large punch (8mm), which may partly overcome the
variety caused by the hematocrit fraction. We applied no correction
factor for hematocrit as we aimed to perform a clinical validation of a
standard DBS method versus simultaneously collected blood samples
obtained by venipuncture. It was not our intention to develop a DBS
method and to investigate the influence of hematocrit. In addition,
when one decides to use DBS for measurement of vitamin D, hematocrit
is hard to establish so a correction cannot be applied. However, al-
though we did not measure individual hematocrit values, another group
examined samples containing a range of RBC and known 25(OH)D3
concentrations; in that study, within a hematocrit range of 0.4-0.6
(considered normal for an adult population), very little change in levels
was seen [7].
Using a 25(OH)D3 concentration of< 30 nmol/L for vitamin D de-
ficiency, the sensitivity of recalculated DBS was 87.8% and specificity
was 89.2%. The PPV for recalculated DBS was 62.3%, implying that the
advice to start vitamin D supplementation might be given too early in
almost 38% of the cases. However, 96% of these false positive-cases had
25(OH)D3 concentrations< 50 nmol/L, which still can be regarded as
insufficient. Furthermore, recommending vitamin D supplements in a
false-positive case will very likely do no harm. The NPV for recalculated
DBS 25(OH)D3 concentrations< 30 nmol/L was 97.3%, implying that
in less than 3% of the samples the DBS method misclassified the vitamin
D status as not deficient.
Because of the wide range of 25(OH)D3 concentrations, as shown by
the limits of agreement in the Bland-Altman plot, DBSL is less suitable
for assessing vitamin D status and monitoring vitamin D therapy in
individuals. Thus, DBS 25(OH)D3 values may be almost 21 nmol/L
below or 24 nmol/L above serum values, which is not an acceptable
range for clinical decision making.
At this time, it is too early to decide whether DBS could be used in a
vitamin D deficiency screening program. First, PPV and NPV are among
others dependent on the prevalence of vitamin D deficiency in the
target population. Therefore, PPV and NPV that we found may not be
applicable for important target groups like young children (because of
the risk of rickets) and institutionalized older persons (because of their
often low production of vitamin D in the skin and their higher risk of
fractures). Second, the cut-off point of DBS as a first step in screening
should be chosen with a view to an optimum of PPV and NPV. E.g., one
may choose an NPV as high as possible, even if this means a lower PPV,
as false-positive cases are not very problematic: repeat measurement by
venipuncture is relatively easy and cost of eventual vitamin D therapy is
low. For example, if vitamin D deficiency is defined as serum 25(OH)
D<30 nmol/L (venipuncture), in our respondents a cut-off of 40 nmol/
L (DBS) would have resulted in a PPV of 38.5% and an NPV of 99.4%
(data not shown).
To our knowledge this is the first study performed among a Chinese
population to compare DBS and serum for measurement of 25(OH)D3. A
strength of this study is the relatively large number of participants who
completed 25(OH)D3 measurement from DBS and from simultaneously
collected blood samples obtained by venipuncture, with an adequate
number of vitamin D deficient people. However, our study also has
several limitations. First, as we did not measure hematocrit levels of
individual participants it is uncertain whether participants had a blood
hematocrit level beyond the reference values, thereby influencing the
assay results. Second, the punch of 8mm as used by DBSL, although
relatively large, carries the risk that small spots may be completely
included in the punch, whereas large spots are only partially included,
resulting in a negative bias in large spots. However, only 12 DBS (4%)
samples were excluded due to an inadequate punch. Third, DBSL did
not differentiate between 25(OH)D3 and its C-3-epimer, which may
result in an over-estimation of the total 25(OH)D concentration.
Because 3-epi-25(OH)D3 concentrations are believed to account for a
significant percentage of the total 25(OH)D only in infants under one
year [20], the assay used by DBSL is less suitable for this age category.
Fourth, as vitamin D2 is generally not used in the Netherlands, we did
not measure 25(OH)D2 concentrations, which may be regarded as a
limitation of our study. Finally, the results may not be generalizable to
other populations or age categories, especially not to infants under one
year, institutionalized older persons and populations where supple-
ments containing 25(OH)D2 are commonly used.
In conclusion, DBS is an easy and less invasive method for collecting
blood samples than venipuncture and requires smaller blood volumes
for measurement of 25(OH)D3. The assay used showed a good agree-
ment between the measurement of 25(OH)D3 in DBS and serum, and
may adequately exclude vitamin D deficiency in community-dwelling
adults and noninstitutionalized elderly persons. However, DBS is less
suitable for individualized assessment of vitamin D status because of the
wide interval of the limits of agreement in Bland-Altman analysis.
Based on our results, it is too early to recommend the DBS method for
screening for vitamin D deficiency. Further research is needed, espe-
cially for use in young children and institutionalized older persons.
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